Exelixis EXEL Europe — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's europe — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's europe — total revenues?
- Exelixis (EXEL) reported europe — total revenues of $39.57M in Q1 2026.
- How has Exelixis's europe — total revenues changed year-over-year?
- Exelixis's europe — total revenues increased by 21.0% year-over-year, from $32.71M to $39.57M.
- What is the long-term trend for Exelixis's europe — total revenues?
- Over 4 years (2021 to 2025), Exelixis's europe — total revenues has grown at a -15.5% compound annual growth rate (CAGR), from $302.07M to $154.17M.
- What does europe — total revenues mean?
- The total amount of money earned from pharmaceutical sales and partnerships within the European market.
- How do you interpret europe — total revenues?
- An increase suggests successful market expansion, strong adoption of oncology therapies, or favorable pricing outcomes in Europe, while a decrease may signal increased competition, patent expirations, or regulatory hurdles.
- How does europe — total revenues compare across companies?
- Comparable to regional revenue reporting for other mid-to-large cap biopharmaceutical firms, though it is highly sensitive to the specific lifecycle stage of the company's primary oncology assets in that region.